Italia markets closed

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,9900+0,0200 (+0,40%)
Alla chiusura: 04:00PM EDT
5,0100 +0,02 (+0,40%)
Dopo ore: 04:12PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,9700
Aperto5,0400
Denaro4,8300 x 800
Lettera4,9900 x 1400
Min-Max giorno4,9300 - 5,0400
Intervallo di 52 settimane0,1600 - 5,9000
Volume27.294
Media Volume1.116.320
Capitalizzazione24,231M
Beta (5 anni mensile)1,71
Rapporto PE (ttm)N/D
EPS (ttm)-0,0790
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A28,00
  • GlobeNewswire

    Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

    – Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended Jun

  • GlobeNewswire

    Aeterna Zentaris Announces Effective Date of Share Consolidation

    TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidati

  • GlobeNewswire

    Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

    TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the proposed consolidation of the Company’s shares (the “Share Consolidation”) was approved at its reconvened annual meeting of shareholders (the “Meeting”) held today. Following the Meeting, the Company’s board